Vectorbuilder Inc

Activities: Research & Development

Revolutionise gene delivery from research to therapy

Visit website

Profile


VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside.  Learn More

 

 

Trending Articles

  1. Innovation in generics: increased efficiency through peptide API synthesis expertise Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
  2. COVID-19 still a significant risk for the immunocompromised, study finds AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
  3. US court lifts modified consent decree on Xellia’s Cleveland facility The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
  4. Lonza's AI-enabled small molecule development tool launches The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
  5. Autoscribe Informatics’ new Australia office supports business growth The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

Related Content

Manufacturing

Why has gene delivery become such a hot property?

VectorBuilder's latest cash injection drives them towards a CDMO facility for the manufacturing of plasmids, mRNA, AAV, lentivirus, cell lines, and a variety of viral and non-viral vectors
Manufacturing

Plasmid and lentiviral vector CDMO VectorBuilder orders rise by 70%

The company's plasmid and lentiviral vector CDMO products have received Investigational New Drug (IND) approval from the FDA
Research & Development

VectorBuilder to construct R&D and manufacturing campus

Construction is expected to cost $500m and will be split into two phases over the next four years
Subscribe now